Description of Research Expertise
Diabetes and obesity clinical trials.
Selected Publications
Marianne Riordan, Elizabeth Sevrukov, Anastassia Amaro: Glucagon-Like Peptide-1 Receptor Agonists in Post-Bariatric Hypoglycemia: A Retrospective Chart Review 32nd European Congress on Obesity : 2025.
Caturano A, Amaro A, Berra CC, Conte C.: Sarcopenic obesity and weight loss-induced muscle mass loss Curr Opin Clin Nutr Metab Care : 2025.
Emily Gleason, BA Lindsay Levine, BA ∙ Iris T. Lee, MD MSCE ∙ Nathanael Koelper, MPH ∙ Anastassia Amaro, MD ∙ Anuja Dokras, MD, MHCI, PhD: Effect of Glucagon-Like Peptide 1 Agonist Medications on Weight Loss in Patients with and Without Polycystic Ovary Syndrome Fertility and Sterility : 2025.
Ariana M Chao 1, Simeon Taylor 2, Molly Moore 3, Anastassia Amaro 4, Thomas A Wadden 3: Evolving Approaches for Pharmacological Therapy of Obesity Annu Rev Pharmacol Toxicol
: 2024.
Thomas A Wadden, Ariana M Chao, Molly Moore, Jena S Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M Jakicic: The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities Curr Obes Rep : 2023.
Authors: Emily Gleason BA, Lindsay Levine BA, Iris T. Lee, MD, Nathanael Koelper, MPH, Anastassia Amaro, MD, Anuja Dokras, MD, MHCI, PhD: Effect of Glucagon-Like Peptide 1 Receptor Agonist Pharmacotherapy on Weight Loss in Patients with and Without Polycystic Ovary Syndrome ASRM 2023 Scientific Congress : 2023.
R. Jones Jr, C. Maskart, J. Radway, A. Amaro, S. Cardillo: A Multimodal Curriculum to Improve Medical Student Gender-affirming Communication Skills, poster presentation. ENDO Society : 2023.
A. Rivadeneira Rodriguez, M. Walker, R. Gallop, A. Amaro: Single Center Retrospective Matched Cohort Study of glp1ra-Induced Weight Loss in Patients With Post-bariatric Weight Regain vs Non-surgical Controls, poster presentation. ENDO Society : 2023.
Amaro A, Sugimoto D, Wharton S.: Efficacy and safety of semaglutide for weight management: evidence from the STEP program Postgrad Med 134(Sup1) : 5-17,2023.
Amaro A, Skolnik NS, Sugimoto D.: Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med 134(sup1) : 18-27,2023.
Academic Contact Information
Penn Metabolic Medicine
3737 Market St
Philadelphia,
PA
19104
Phone: 215-294-9525
Patient appointments: 800-789-7366